GO:2000308 negative regulation of tumor necrosis factor (ligand) superfamily member 11 production: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000308 describes any biological process that stops, prevents, or reduces the production of TNFSF11, also known as RANKL.
• RANKL is the master cytokine for osteoclast differentiation, survival, and activation, making its negative regulation central to bone homeostasis.
• Interferons, particularly IFN-beta and IFN-gamma, are classic negative regulators of RANKL production and signaling in osteoclast precursors.
• TSLP acts as a negative regulator of RANKL-induced osteoclastogenesis, highlighting cytokine crosstalk in bone metabolism.
• Sestrin2 inhibits RANKL-induced osteoclastogenesis through AMPK activation and ROS inhibition, linking metabolic stress to RANKL regulation.
• Dysregulation of RANKL production is implicated in osteoporosis, osteolytic bone metastases, inflammatory bone destruction, and osteogenesis imperfecta.
Description
GO:2000308, negative regulation of tumor necrosis factor (ligand) superfamily member 11 production, is a biological process term that captures any mechanism which stops, prevents, or reduces the frequency, rate, or extent of TNFSF11 (RANKL) production. RANKL is a member of the tumor necrosis factor superfamily and serves as the essential cytokine for osteoclast differentiation, activation, and survival. Because RANKL is the final common mediator of bone resorption, understanding how its production is negatively regulated is fundamental to bone biology and to the pathophysiology of skeletal diseases. Researchers study this process to identify therapeutic targets for osteoporosis, osteolytic bone metastases, and inflammatory bone destruction. The term also encompasses negative regulation of RANKL in immune cells, where RANKL suppresses effector cytokine production in group 3 innate lymphoid cells, revealing broader immunological roles. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:2000308, its mechanisms, key genes, disease relevance, and experimental approaches.
negative regulation of tumor necrosis factor (ligand) superfamily member 11 production At A Glance
| GO ID | GO:2000308 |
|---|---|
| GO term | negative regulation of tumor necrosis factor (ligand) superfamily member 11 production |
| Ontology | biological_process |
| Synonym | negative regulation of RANKL production; negative regulation of TNFSF11 production |
| Major function | Reduction of RANKL (TNFSF11) protein production, thereby limiting osteoclastogenesis and bone resorption |
| Key regulators | Interferons (IFN-beta, IFN-gamma), TSLP, Sestrin2, PRL2, and other cytokines and metabolic sensors |
| Associated diseases | Osteoporosis, osteolytic bone metastases, inflammatory bone destruction, osteogenesis imperfecta |
| Research methods | Knockout and knock-in models, RNA-seq, proteomics, osteoclast differentiation assays, imaging |
What Is GO:2000308?
GO:2000308 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of tumor necrosis factor (ligand) superfamily member 11 production. In simpler terms, it covers all biological mechanisms that decrease the amount of RANKL protein made by a cell. This includes transcriptional repression of the TNFSF11 gene, post-transcriptional regulation of TNFSF11 mRNA, inhibition of RANKL protein translation, and increased degradation of RANKL protein. The term is synonymous with negative regulation of RANKL production and negative regulation of TNFSF11 production. It is a biological_process ontology term, meaning it describes a biological objective rather than a molecular function or cellular component.
Why Is negative regulation of tumor necrosis factor (ligand) superfamily member 11 production Important in Cell Biology?
GO:2000308 is critically important because RANKL is the indispensable cytokine for osteoclast formation and function, and its negative regulation directly controls bone mass and skeletal integrity. An imbalance favoring RANKL production over its negative regulation leads to excessive bone resorption, which underlies common and devastating diseases such as postmenopausal osteoporosis, rheumatoid arthritis, and osteolytic bone metastases. Conversely, understanding the negative regulation of RANKL production offers therapeutic opportunities to suppress pathological bone loss without completely abolishing immune functions. The process also intersects with immune regulation, as RANKL suppresses effector cytokine production in group 3 innate lymphoid cells, indicating that its negative regulation may influence mucosal immunity and inflammation. Therefore, research on GO:2000308 bridges bone biology, immunology, and translational medicine.
• Controls osteoclast differentiation and bone resorption, making it central to bone homeostasis.
• Dysregulation contributes to osteoporosis and osteolytic bone metastases.
• Interferons negatively regulate RANKL production, linking antiviral and immune signaling to bone protection.
• TSLP acts as a negative regulator of RANKL-induced osteoclastogenesis, revealing cytokine crosstalk.
• Sestrin2 inhibits RANKL-induced osteoclastogenesis via AMPK and ROS, connecting metabolic stress to bone.
• HSC70-mediated autophagic degradation of oxidized PRL2 affects osteoclastogenesis and inflammatory bone destruction.
• RANKL suppresses effector cytokine production in group 3 innate lymphoid cells, expanding its immunological roles.
• Osteogenesis imperfecta involves defective bone formation and altered remodeling, where RANKL regulation is relevant.
• Provides targets for emerging breakthrough drugs for osteoporosis and osteolytic bone metastases.
• Enables development of CRISPR-based models to dissect causal genes in RANKL regulation.
What Happens During negative regulation of tumor necrosis factor (ligand) superfamily member 11 production?
Transcriptional repression of TNFSF11
In simple terms: The cell reduces the first step of making RANKL by turning down the gene that codes for it.
Negative regulation of RANKL production often begins at the level of transcription. Interferons, particularly IFN-beta and IFN-gamma, can suppress TNFSF11 gene expression in osteoclast precursors and stromal cells, thereby reducing RANKL protein levels. This transcriptional repression is a key mechanism by which the immune system limits osteoclastogenesis under inflammatory conditions. The signaling crosstalk between RANKL and interferons involves multiple pathways that converge on the TNFSF11 promoter and enhancer regions.
Post-transcriptional and post-translational control
In simple terms: Even after the RANKL message is made, the cell can destroy it or the protein before it does its job.
Beyond transcription, negative regulation of RANKL production can occur through post-transcriptional mechanisms that reduce TNFSF11 mRNA stability or translation efficiency. Additionally, post-translational degradation of RANKL protein contributes to lowering its effective concentration. For example, HSC70-mediated autophagic degradation of oxidized PRL2 is responsible for osteoclastogenesis and inflammatory bone destruction, indicating that protein quality control pathways intersect with RANKL regulation. These layers ensure that RANKL levels are tightly controlled in response to physiological cues.
Cytokine-mediated inhibition of RANKL-induced osteoclastogenesis
In simple terms: Certain cytokines act as brakes on the RANKL signal, preventing osteoclasts from forming.
TSLP is a negative regulator of RANKL-induced osteoclastogenesis, acting downstream or in parallel to reduce the effective RANKL signal. Similarly, interferons negatively regulate RANKL production and signaling, thereby inhibiting osteoclast differentiation. These cytokine-mediated mechanisms are essential for maintaining bone homeostasis and preventing excessive bone resorption during immune responses.
Metabolic and stress-responsive inhibition
In simple terms: Cellular stress and metabolic sensors can put the brakes on RANKL production.
Sestrin2 inhibits RANKL-induced osteoclastogenesis through AMPK activation and ROS inhibition, linking metabolic stress and redox balance to negative regulation of RANKL production. This suggests that energy-sensing pathways can suppress RANKL-driven osteoclastogenesis, providing a mechanistic link between metabolism and bone remodeling. Such stress-responsive inhibition may protect against bone loss under conditions of oxidative stress or nutrient limitation.
RANKL in immune cell regulation
In simple terms: RANKL also affects immune cells, and its negative regulation can influence inflammation.
The tumor necrosis factor superfamily member RANKL suppresses effector cytokine production in group 3 innate lymphoid cells, demonstrating that RANKL has immunoregulatory functions beyond bone. Negative regulation of RANKL production in these cells may therefore modulate innate lymphoid cell effector functions and mucosal immunity. This expands the biological significance of GO:2000308 to include immune homeostasis.
Key Genes Involved in GO:2000308 negative regulation of tumor necrosis factor (ligand) superfamily member 11 production
The following genes and proteins are experimentally implicated in the negative regulation of TNFSF11 (RANKL) production or in RANKL-induced osteoclastogenesis, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFSF11 (RANKL) | Encodes the ligand that drives osteoclast differentiation and survival | Central target of negative regulation; knockout and knock-in models are essential |
| TNFRSF11B (OPG) | Decoy receptor for RANKL that inhibits osteoclastogenesis | Competes with RANK for RANKL; overexpression models reduce bone resorption |
| IFNB1 | Interferon-beta negatively regulates RANKL production and signaling | Key cytokine for negative regulation; knockout increases osteoclastogenesis |
| IFNG | Interferon-gamma suppresses RANKL-induced osteoclast differentiation | Critical for immune-mediated bone protection; knockout models show bone loss |
| TSLP | Thymic stromal lymphopoietin negatively regulates RANKL-induced osteoclastogenesis | Cytokine crosstalk; overexpression reduces osteoclast formation |
| SESN2 | Sestrin2 inhibits RANKL-induced osteoclastogenesis via AMPK and ROS | Metabolic stress sensor; knockout enhances osteoclastogenesis |
| PRL2 | Oxidized PRL2 is degraded by HSC70-mediated autophagy, affecting osteoclastogenesis | Links autophagy and redox regulation to RANKL signaling |
| HSC70 (HSPA8) | Chaperone mediating autophagic degradation of oxidized PRL2 | Protein quality control in osteoclastogenesis; knockout impairs degradation |
| AMPK (PRKAA1/2) | Activated by Sestrin2 to inhibit RANKL-induced osteoclastogenesis | Energy sensor; pharmacological activation mimics negative regulation |
| ROS (reactive oxygen species) | Inhibited by Sestrin2 to suppress osteoclastogenesis | Redox balance modulates RANKL signaling; antioxidants may mimic |
| CTSK | Cathepsin K, a marker of mature osteoclasts | Readout of osteoclast differentiation in knockout/overexpression studies |
| ACP5 (TRAP) | Tartrate-resistant acid phosphatase, osteoclast marker | Histochemical marker for osteoclastogenesis assays |
| NFATC1 | Master transcription factor for osteoclast differentiation downstream of RANKL | Knockout blocks osteoclastogenesis; target of negative regulation |
| FOS | AP-1 component required for osteoclast differentiation | Transcription factor downstream of RANKL; knockout causes osteopetrosis |
| MITF | Transcription factor cooperating with NFATC1 in osteoclasts | Regulates osteoclast gene expression; potential target |
| TRAF6 | E3 ubiquitin ligase essential for RANKL signaling | Knockout abolishes osteoclastogenesis; upstream of NF-kB |
| NFKB1 | NF-kB subunit mediating RANKL-induced osteoclastogenesis | Knockout impairs osteoclast formation; target of negative crosstalk |
| MAPK14 (p38) | Stress kinase activated by RANKL | Inhibitors block osteoclastogenesis; readout of negative regulation |
How Is negative regulation of tumor necrosis factor (ligand) superfamily member 11 production Regulated?
The negative regulation of RANKL production is itself controlled by multiple signaling pathways. Interferons (IFN-beta and IFN-gamma) are potent negative regulators that suppress RANKL production and signaling through crosstalk with RANKL-induced pathways. TSLP acts as a negative regulator of RANKL-induced osteoclastogenesis, providing an additional layer of cytokine-mediated control. Metabolic sensors such as AMPK, activated by Sestrin2, inhibit RANKL-induced osteoclastogenesis and reduce ROS, linking energy status to RANKL regulation. Autophagic degradation of oxidized PRL2 by HSC70 also modulates osteoclastogenesis, indicating that protein quality control pathways regulate RANKL signaling. These regulatory mechanisms ensure that RANKL production is tightly coupled to physiological demand and can be suppressed under conditions that favor bone preservation.
negative regulation of tumor necrosis factor (ligand) superfamily member 11 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFSF11 (RANKL) | Osteoporosis, osteolytic bone metastases | Knockout and overexpression in osteoclast precursors; bone metastasis models |
| IFNB1 | Bone loss associated with viral infection or interferon therapy | Knockout mice; interferon treatment in osteoclast cultures |
| TSLP | Inflammatory bone destruction | TSLP knockout and overexpression in osteoclast differentiation assays |
| SESN2 | Oxidative stress-related bone loss | Sestrin2 knockout and AMPK activation studies |
| PRL2/HSC70 | Inflammatory bone destruction | Knockout of HSC70 or PRL2; autophagy inhibitors |
Osteoporosis and osteolytic bone metastases
Excessive RANKL production relative to its negative regulation drives osteoclastogenesis and bone resorption, contributing to osteoporosis and osteolytic bone metastases. Emerging breakthrough drugs for these conditions target RANKL or its signaling, underscoring the therapeutic importance of understanding GO:2000308. Interferons, which negatively regulate RANKL production, may offer additional therapeutic avenues.
Inflammatory bone destruction
Inflammatory conditions such as rheumatoid arthritis are characterized by elevated RANKL and bone destruction. HSC70-mediated autophagic degradation of oxidized PRL2 is responsible for osteoclastogenesis and inflammatory bone destruction, linking protein oxidation and autophagy to RANKL-driven pathology. Negative regulation of RANKL production by TSLP or interferons may protect against inflammatory bone loss.
Osteogenesis imperfecta
Osteogenesis imperfecta is a genetic disorder of bone fragility often caused by collagen mutations, but bone remodeling and RANKL regulation influence disease severity. Understanding how negative regulation of RANKL production affects bone mass in osteogenesis imperfecta may inform therapeutic strategies.
Immune regulation and innate lymphoid cells
RANKL suppresses effector cytokine production in group 3 innate lymphoid cells, indicating that negative regulation of RANKL production may modulate mucosal immunity and inflammation. Dysregulation of this process could contribute to immune-mediated diseases beyond bone.
From negative regulation of tumor necrosis factor (ligand) superfamily member 11 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase RANKL production? | Knockout cell model (e.g., CRISPR-Cas9 KO in osteoclast precursors) |
| Does a specific point mutation in TNFSF11 affect its regulation? | Point mutation knock-in model |
| Does overexpression of a negative regulator reduce RANKL levels? | Overexpression cell model (e.g., lentiviral TSLP or Sestrin2) |
| Where and when is RANKL produced in vivo? | Tagged knock-in reporter (e.g., GFP-TNFSF11) |
| Does a candidate gene causally affect osteoclastogenesis? | CRISPR knockout followed by osteoclast differentiation assays |
| Can a drug mimic negative regulation of RANKL? | Pharmacological inhibition in wild-type and knockout cells |
How to Study the negative regulation of tumor necrosis factor (ligand) superfamily member 11 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| TRAP staining | Osteoclast differentiation | Screening negative regulators of RANKL-induced osteoclastogenesis |
| Resorption pit assay | Bone resorption activity | Functional validation of osteoclasts |
| RNA-seq | Transcriptome including TNFSF11 mRNA | Identifying transcriptional repression mechanisms |
| Western blot | RANKL protein levels | Assessing post-transcriptional regulation |
| Cycloheximide chase | Protein stability | Measuring RANKL degradation rates |
| Immunofluorescence | RANKL localization and NFATc1 translocation | Visualizing signaling in osteoclast precursors |
| CRISPR knockout | Gene function loss | Testing causal role of candidate negative regulators |
| Overexpression | Gain of function | Testing if a gene suppresses RANKL production |
Osteoclast differentiation assays
Osteoclast differentiation assays using bone marrow-derived macrophages or RAW264.7 cells treated with M-CSF and RANKL are standard for studying negative regulation of RANKL production. Readouts include TRAP staining, cathepsin K expression, and resorption pit assays. These assays can be combined with cytokine treatments (e.g., TSLP, IFN-beta) to test negative regulation.
RNA-seq and transcriptomics
RNA sequencing can quantify TNFSF11 mRNA levels and identify transcriptional changes induced by negative regulators such as interferons or TSLP. Comparative transcriptomics between wild-type and knockout cells reveals pathways that suppress RANKL production. This method is high-throughput and unbiased.
Proteomics and protein degradation assays
Proteomics can measure RANKL protein levels and post-translational modifications, while degradation assays (e.g., cycloheximide chase) assess RANKL stability. HSC70-mediated autophagic degradation of oxidized PRL2 exemplifies how protein quality control affects osteoclastogenesis. These methods complement transcriptomic data.
Imaging and reporter models
Fluorescence imaging of tagged RANKL or reporter mice allows spatial and temporal tracking of RANKL production in bone and immune tissues. Immunohistochemistry for RANKL and TRAP in bone sections visualizes osteoclastogenesis in situ. Live-cell imaging can monitor NFATc1 nuclear translocation downstream of RANKL.
How CRISPR Can Be Used to Study GO:2000308 negative regulation of tumor necrosis factor (ligand) superfamily member 11 production
Knockout
CRISPR knockout of candidate negative regulators such as IFNB1, TSLP, or SESN2 can test whether their loss increases RANKL production and osteoclastogenesis. Knockout of TNFSF11 itself abolishes osteoclastogenesis and causes osteopetrosis, serving as a positive control. These models are essential for establishing causality in GO:2000308.
Point Mutation
Point mutations in TNFSF11 or its regulators can dissect specific residues required for negative regulation, such as phosphorylation sites or ubiquitination sites. CRISPR prime editing or homology-directed repair can introduce these mutations to study their effects on RANKL production and osteoclastogenesis. This approach provides mechanistic insight beyond simple knockout.
Knock-in
Knock-in of reporter tags (e.g., GFP or luciferase) into the TNFSF11 locus enables real-time monitoring of RANKL production in live cells and animals. Knock-in of disease-associated mutations can model human skeletal disorders linked to RANKL dysregulation. These models are valuable for drug screening and mechanistic studies.
Overexpression
Overexpression of negative regulators such as TSLP, Sestrin2, or interferon-beta can suppress RANKL-induced osteoclastogenesis and reduce bone resorption. Lentiviral or transgenic overexpression models allow gain-of-function studies to complement knockout approaches. These models help validate therapeutic targets for osteoporosis and inflammatory bone destruction.
How EDITGENE Supports negative regulation of tumor necrosis factor (ligand) superfamily member 11 production Research
Researchers studying negative regulation of tumor necrosis factor (ligand) superfamily member 11 production-related genes often need to determine whether a candidate gene is causally involved in suppressing RANKL production or osteoclastogenesis. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes implicated in GO:2000308.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of tumor necrosis factor (ligand) superfamily member 11 production research.
Frequently Asked Questions About negative regulation of tumor necrosis factor (ligand) superfamily member 11 production
What is GO:2000308?
GO:2000308 is the Gene Ontology term for negative regulation of tumor necrosis factor (ligand) superfamily member 11 production, meaning any process that reduces the production of RANKL (TNFSF11).
What genes are involved in negative regulation of RANKL production?
Key genes include IFNB1, IFNG, TSLP, SESN2, PRL2, and HSC70, which suppress RANKL production or signaling.
How do interferons negatively regulate RANKL?
Interferons such as IFN-beta and IFN-gamma suppress TNFSF11 gene expression and inhibit RANKL-induced osteoclast differentiation through signaling crosstalk.
What is the role of TSLP in RANKL regulation?
TSLP acts as a negative regulator of RANKL-induced osteoclastogenesis, reducing osteoclast formation.
How does Sestrin2 inhibit osteoclastogenesis?
Sestrin2 inhibits RANKL-induced osteoclastogenesis through AMPK activation and ROS inhibition.
What diseases are linked to RANKL dysregulation?
Osteoporosis, osteolytic bone metastases, inflammatory bone destruction, and osteogenesis imperfecta are linked to altered RANKL production.
How can CRISPR be used to study GO:2000308?
CRISPR knockout, point mutation, knock-in, and overexpression models can test whether candidate genes causally regulate RANKL production and osteoclastogenesis.
What methods measure RANKL production?
TRAP staining, RNA-seq, Western blot, cycloheximide chase, and reporter imaging are commonly used to measure RANKL production and osteoclastogenesis.
Is RANKL involved in immune regulation?
Yes, RANKL suppresses effector cytokine production in group 3 innate lymphoid cells, indicating roles beyond bone.
What cell models are suitable for studying negative regulation of RANKL?
Bone marrow-derived macrophages, RAW264.7 cells, and CRISPR-engineered osteoclast precursors are suitable models.
Conclusion
GO:2000308, negative regulation of tumor necrosis factor (ligand) superfamily member 11 production, is a critical biological process that controls RANKL levels and thereby osteoclastogenesis, bone resorption, and immune homeostasis. Key negative regulators include interferons, TSLP, Sestrin2, and HSC70-mediated degradation of PRL2, which act through transcriptional, post-transcriptional, and metabolic mechanisms. Dysregulation of this process contributes to osteoporosis, osteolytic bone metastases, and inflammatory bone destruction, making it a prime therapeutic target. CRISPR-based models from EDITGENE enable precise dissection of causal genes and accelerate translational research in bone biology.
References
- 1. Feingold KR et al.. 2000. Osteogenesis Imperfecta.. PMID: 25905334
- 2. Bando JK et al.. 2018. The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells.. Immunity 48(6):1208-1219.e4 PMID: 29858011
- 3. Kim K et al.. 2024. Sestrin2 inhibits RANKL-induced osteoclastogenesis through AMPK activation and ROS inhibition.. Free Radic Biol Med 211:77-88 PMID: 38101586
- 4. Ohno T et al.. 2020. TSLP is a negative regulator of RANKL-induced osteoclastogenesis.. Biochem Biophys Res Commun 530(3):508-512 PMID: 32600615
- 5. Abraham AK et al.. 2009. Mechanisms of interferon-beta effects on bone homeostasis.. Biochem Pharmacol 77(12):1757-62 PMID: 19428330
- 6. Takayanagi H et al.. 2002. Signaling crosstalk between RANKL and interferons in osteoclast differentiation.. Arthritis Res 4 Suppl 3(Suppl 3):S227-32 PMID: 12110142
- 7. Boyce BF et al.. 2003. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases.. Kidney Int Suppl PMID: 12753255
- 8. Li Q et al.. 2023. HSC70 mediated autophagic degradation of oxidized PRL2 is responsible for osteoclastogenesis and inflammatory bone destruction.. Cell Death Differ 30(3):647-659 PMID: 36182990
